Most patients with newly diagnosed Ovarian cancer will have advanced disease. Nearly 70% of women relapse within 3 years of first-line treatment. There is a significant need for better first-line treatment to improve outcomes for women with advanced ovarian cancer.
Approximately 50% of patients with high grade serous ovarian cancer have HRD. BRCA1 and BRCA2 mutations are the most common alterations among HRD. BRCA mutation and HRD testing are essential to be in routine clinical practice. Per guidelines, maintenance treatment with PARP inhibitors (olaparib, niraparib, and rucaparib) or olaparib +bevacizumab is recommended among patients with advanced ovarian cancer with BRCA mutation or HRD +ve disease.
Also, maintenance treatment with PARP inhibitors or bevacizumab alone is recommended among patients with advanced ovarian cancer with HRD -ve &wild BRCA. Treatment of patients with HRD-ve tumors remains in an unmet need and face a poor prognosis, with 90% experiencing relapse within 3 years, highlighting the urgent need for new treatment options.
Presented at: Gynecologic Oncology Conference 2026 – Online
June 14, 2026 | 10.00 AM CEST
About the Author
